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Summary
AIMS OF THE STUDY: Paediatric musculoskeletal infec-
tions by Panton-Valentine leucocidin (PVL)-producing
Staphylococcus aureus constitute a rare, but highly critical
event. They are characterised by a rapid course of marked
inflammation, worsening under conservative therapy and
a high rate of recurrence. This study aimed to illustrate the
importance of paediatric PVL-producing S. aureus muscu-
loskeletal infections in western Switzerland.
METHODS: Case records, clinical parameters and biolog-
ical assessments of children with musculoskeletal infec-
tions due to PVL-producing S. aureus who attended the
University Hospitals of Lausanne and Geneva from 2008
to 2016 were studied retrospectively.
RESULTS: Of the nine cases (seven male), four presented
with haematogenous acute osteomyelitis, two with septic
arthritis, and three with skin and soft tissue infections. Lab-
oratory analysis revealed mean values for white blood cell
count of 12,700/mm3, C-reactive protein (CRP) 171mg/
l, erythrocyte sedimentation rate (ESR) 62 mm/h and
platelet count 241,000/mm3. Notably, fever and laboratory
values were higher for osteoarticular infections. PVL was
produced by methicillin-sensitive S. aureus (MSSA) in
eight cases and by community-acquired methicillin-resis-
tant S. aureus (CA-MRSA) in one case. PVL was identified
in blood cultures (six cases), operative samples (seven
cases) and an oral swab (one case). Treatment relied
on surgical procedures, endorsed by two-agent antimicro-
bial therapy for up to 9 weeks. Complications included re-
current infections (five cases), pathological fracture (one
case) and growth arrest (two cases), as well as an impor-
tant psychological impact (one case).
CONCLUSION: The results of this study highlight the low
prevalence of PVL-producing S. aureus musculoskeletal
infections in the paediatric population in our region. Never-
theless, given the importance of complications, the recur-
rence rate and the duration of treatment, clinicians caring
for children need to be especially well versed with the pe-
culiarity of this entity. Retrospective case series. Level of
evidence: IV
Keywords: Panton-Valentine leucocidin, musculoskeletal
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Introduction
Panton-Valentine leucocidin (PVL) is a cytotoxin pro-
duced by any strain of Staphylococcus aureus that causes
leucocyte destruction and important tissue necrosis. This
pathogen is currently responsible for extensive necrotic
skin lesions, potentially fatal necrotising pneumonia and
severe musculoskeletal infections. PVL may be produced
by various S. aureus strains, both methicillin-sensitive S.
aureus (MSSA) and community-acquired methicillin-re-
sistant S. aureus (CA-MRSA) [1]. In a European study, the
prevalence of PVL-positive community-acquired S. aureus
amounted to 18.6% and 7.8% of the isolates were MR-
SA [2]. The correlation between production of PVL and
the severity of infection is controversial, since the latter
seems most likely to depend on the patient’s age. A re-
cent meta-analysis in adults illustrated the lack of coher-
ence between infection by PVL-positive strains and the
outcome of pneumonia, musculoskeletal disease or bac-
teraemia [3]. Nevertheless, the paediatric literature reports
severe local necrosis with a pronounced inflammatory re-
sponse induced by PVL, with consequent short- and long-
term complications. As a matter of fact, several studies
highlight the peculiarity of PVL-positive musculoskeletal
infections in children and demonstrate that affected pa-
tients presented more elevated inflammatory parameters
and a higher complication rate requiring repeated surgical
interventions, intensive care unit admission and a conse-
quently long hospital stay [4–9]. At our two university
medical centres, we identified the first case of PVL-posi-
tive musculoskeletal infection only in 2008. The purpose
of this article was to present a series of nine cases of pae-
diatric musculoskeletal infections due to PVL-producing
S. Aureus, highlighting their clinical aspects, the results of
laboratory studies and the outcome of therapy (both surgi-
cal procedures and length of antibiotic treatment), as well
as the complications noted.
Patients and methods
After approval from the respective Children’s Hospital
Ethics Review Committee, we retrospectively collected
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the medical charts of all children aged from 0–16 years
old admitted in our two university hospitals (CHUV Lau-
sanne and HUG Geneva) between January 2008 and De-
cember 2016 for PVL-positive musculoskeletal infections.
The criteria established by Morrey were used to estimate
children’s risk of having a bone or joint infection [10].
Diagnoses of osteoarticular infections were confirmed us-
ing imaging techniques (plain radiography, ultrasonogra-
phy, 99mTC bone scan, computed tomography, magnetic
resonance imaging). Children diagnosed as having mus-
culoskeletal infections were further categorised according
to the following primary diagnoses: acute haematogenous
osteomyelitis, septic arthritis, and skin and soft tissue in-
fections. Demographics such as age, gender and place of
origin were recorded for each patient as well as clinical
parameters such as onset of symptoms before admission,
fever at the time of admission, the fever duration under
treatment, and the time elapsed between the onset of symp-
toms and diagnosis. Biological work-up included white
blood cell (WBC) count, left-band shift percentage,
platelet count, C-reactive protein (CRP) level, and erythro-
cyte sedimentation rate (ESR).
Microbiological methods
Blood cultures were typically used to isolate the microor-
ganisms responsible for musculoskeletal infections. The
study’s blood culture media used was an automated blood
culture system (BD BACTEC FX). Joint fluid, pus from
soft tissue abscesses or bone aspirate samples were sent to
the laboratory for Gram staining, cell count, and immedi-
ate inoculation onto Columbia blood agar (incubated under
anaerobic conditions), CDC anaerobe 5% sheep blood agar
(incubated under anaerobic conditions), chocolate agar (in-
cubated in a CO2-enriched atmosphere), and brain-heart
broth. These media were incubated for 10 days. The pres-
ence of the PVL gene in S. aureus strains was assessed
with a rapid real time polymerase chain-reaction (PCR) as-
say in one centre until 2014. The remaining two cases in
2016 were analysed as described previously [11].
Treatment
If a suspect fluid was recovered from joint-fluid aspiration,
joint lavage was performed via arthrotomy, or arthroscopy.
Surgical exploration for osteomyelitis generally included
taking subperiosteal or bone aspirate specimens, and aspi-
ration-curettage of any abscesses. For skin and soft tissue
infections, any abscesses were drained. Empirical antibi-
otic therapy started with an intravenous antibiotic chosen
by the attending physician responsible for each patient, af-
ter having obtained samples. The antibiotic regimen was
thereafter adjusted according to antibiotic sensitivity. The
duration of antibiotic treatment and mode of administration
were then determined with regard to each patient’s age,
bacterial characteristics and, above all, their response to
the treatment. Collected data about treatment and follow-
up included duration of intravenous and oral antibiotic
treatment, number of surgical procedures and length of
hospital stay. Long-term outcome was evaluated through
clinical assessment and radiological follow-up.
Results
The study enrolled nine children admitted for PVL-posi-
tive musculoskeletal infection (seven males, two females)
during the 9 years considered, with ages ranging from 2 to
15 years old (median 12 years) (table 1). A retrospective
analysis of all paediatric bacteriological samples positive
for S. aureus available in one centre yielded five PVL-pos-
itive cases out of 571 samples, resulting in a prevalence of
0.9% in our observation period from 2008 to 2016. Vacci-
nation status was recorded for seven of the nine patients,
all of them being vaccinated according to national guide-
lines. The children studied had haematogenous acute os-
teomyelitis in four cases, septic arthritis in two and skin
and soft tissue infections in the remaining three. The mean
admission temperature was 38.7°C (range 37.3–41.0°C),
whereas three patients (33%) had a temperature beneath
38°C on admission.
The median WBC count was 12,700/mm3 (range
6500–22,600) and was considered elevated in five patients
(cut-off: 12,000/mm3). CRP was available for eight pa-
tients and was elevated in six, with a median value of 171
mg/l. The ESR was available for seven patients and was el-
evated in all of them with the mean value of 62 mm/h. Fi-
nally, the mean platelet count was 241,000/mm3.
The pathogen was identified from blood cultures in six
patients and in operative samples cultures in seven cases,
with five patients having both positive blood cultures and
positive operative samples. Bacteriological investigations
demonstrated eight cases of MSSA and one case of CA-
MRSA.
All patients underwent surgical procedures (open surgical
drainage/lavage) and the mean number of interventions per
patient was three (range one to eight). The site of infection
Table 1: Patient characteristics.
Note the important differences between osteoarticular infections (patients 1–6) and skin and soft tissue infections (patients 7–9).
Patient Age (years) Onset (days) T (°C) Fever
(days)
WBC (K/mm3) CRP (mg/l) ESR (mm/h) Diagnosis
1 12 10 38.5 6 19.0 200 78 Osteomyelitis (tibia)
2 10 1 40.2 2 17.0 91 43 Osteomyelitis (humerus)
3 12 2 39.8 50 8.7 189 39 Panosteomyelitis (femur, tibia)
4 13 7 41.0 1 12.5 194 102 Necrotising pandiaphysitis (tibia)
5 10 7 40.0 3 22.6 200 89 Arthritis (hip)
6 15 5 37.3 8 6.4 152 62 Arthritis (knee)
7 2 2 38.7 3 8.5 9 35 Abscess (foot)
8 2 4 37.7 0 – – – Abscess (gluteal) CA-MRSA
9 12 5 37.6 0 12.9 10 – Abscess (finger)
CA-MRSA = community-acquired methicillin-resistant S. aureus; CRP = C-reactive protein, ESR = erythrocyte sedimentation rate, T = temperature on admission, WBC = white
blood cells. Italics = discordance leucocyte count – CRP
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Figure 1: Clinical course of patient 6.Note the rapid evolution from a normal X-ray on day 1 (a) to persisting defects after 5 years (d), and be-
tween magnetic resonance imaging on day 3 (b) and at 10 months (c).
was accessed by bone drilling in cases of osteomyelitis,
arthrotomy for arthritis and local incision for skin and soft
tissue infection. Surgical treatment was complemented by
antibiotherapy, and the antibiotics used are listed in table
2. The duration of intravenous treatment amounted in aver-
age to 16 days (range 0–62 days); all but one patient were
subsequently treated with oral antibiotics (mean duration
25 days). Intravenous antibiotherapy was stopped for the
remaining case after 54 days without switching to oral an-
tibiotics.
Patients sustained various complications (fig. 1) in the
form of infection recurrence (five cases), growth arrest
with limb length discrepancy (two cases) and pathological
fracture (one case) from underlying oncological disease;
one patient developed psychological troubles (suicidality)
in the course of treatment.
Finally we noted that patients with PVL-positive osteoar-
ticular infections had a higher temperature on admission,
and WBC, CRP and ESR were more elevated compared
with patients with skin and soft tissue infections.
The following risk factors were identified among the pa-
tients with osteoarticular infections: one had a history of
acute lymphoid leukaemia and a medical port in situ. Two
patients had a history of previous trauma, one had furun-
culosis at the site of infection and one reported a scratch
injury from intense itching. One patient performed contact
sport. Among the patients with skin and soft tissue infec-
tions, only one case of furunculosis was described.
Discussion
Nine cases of musculoskeletal infections due to PVL-pro-
ducing S. aureus were identified during this 9-year study.
Six were osteoarticular and three affected skin and soft tis-
sue. Our case series illustrates that the prevalence of PVL-
positive musculoskeletal infections is still low in west-
ern Switzerland. This study is consistent with the results
of investigations conducted by the Paediatric Infectious
Disease Group Switzerland, which found only 1.6% of
PVL producers in a cohort of 572 MSSA strains [12].
Our observation is in line with other studies reporting a
low prevalence of PVL-positive strains [13] and on the
predominance of MSSA-PVL in continental Europe [7, 9,
14, 15]. Elsewhere, it is recognised that the proportion
of PVL-producing strains is consistently higher in MRSA
(74–100%) than MSSA (9–46%) [1], and that the rate of
MRSA differs between locations (USA 56–68% MRSA-
positive vs Greece 26%). Thus, the overall reported pro-
portion of PVL-producing S. aureus depends on the preva-
lence of MRSA (USA 78% vs Greece 37%) [1].
One must nevertheless keep in mind that our result may
be biased by two facts, as previously reported [9]. Firstly,
we know neither the number of PVL-positive cases that
are treated in primary institutions nor the proportion of S.
aureus strains referred for PVL testing. We can thus ex-
pect that the number of musculoskeletal infections due to
PVL-positive S. aureus is currently probably underestimat-
ed. Secondly, the rate of MRSA in the paediatric popula-
tion is very low in western Switzerland. Since the preva-
lence of PVL-producing strains depends on the prevalence
of MRSA, this very low prevalence of MRSA might play
Table 2: Management and outcome.
Among all patients, osteoarticular infections stood out by long antibiotic treatment, high complication rate (observation period in years) and long hospital stay due to several re-
lapses.
Patient Surgery (OP) Intravenous antibiotics
(days)
Oral antibiotics
(days)
Complications
(years)
Initial HS
(days)
Total HS (days)
1 5 CXM, FLU, GEN (54) – Sepsis, growth arrest (2) 39 39
2 1 ACA, CLI, FLU (14) CLI (42) Fracture, relapse (5) 14 16
3 3 ACA, AMI, FLU, VAN (50) LEV, RIF (217) Relapse, suicidality (3) 57 83
4 8 CTX, FLU (62) CXM (62) Relapse, sepsis, growth arrest (6) 30 35
5 2 FLU, GEN (18) CLI (25) None 27 27
6 4 ACA, CLI, FLU, IMI, VAN (62) CLI (63) Relapse (5) 53 74
7 5 ACA, CLI, FLU (7) CLI (7) None 17 17
8 1 – ACA, CLI (10) None 1 1
9 2 – FLU (10) None 8 8
ACA = amoxicillin clavulanic acid; AMI = amikacin; CLI = clindamycin; CTX = ceftriaxone; CXM = cefuroxime; FLU = flucloxacillin; GEN = gentamicin; HS = hospital stay; IMI =
imipenem; LEV = levofloxacin; OP = number of operations; RIF = rifampicin; VAN = vancomycin
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a role in the distribution of PVL in our region. The major-
ity of European reports, mainly from France and the UK,
report on MSSA-PVL. Hence, our results confirm both the
low general prevalence of PVL in the paediatric population
and the predominance of MSSA-PVL in Europe [7, 9, 14,
15].
PVL is secreted by any S. aureus strains as two compo-
nents that assemble to a pore-forming complex on poly-
morphonuclear leucocyte membranes [16]. Depending on
the concentration, PVL induces either apoptosis or cytol-
ysis with release of inflammatory factors and subsequent
tissue inflammation [16]. Generally, destruction of leuco-
cytes leads to the characteristic discordance of a low/nor-
mal leucocyte count and high levels of inflammatory para-
meters (e.g., CRP) [17]. In our series, this discrepancy of
low WBC and high CRP level was detected in only two
cases on admission (table 1). Interestingly, the discordance
arose from osteoarticular infections only, since skin and
soft tissue infections presented with a normal white blood
cell count in all three patients and merely increased CRP
levels. The low number of two out of nine patients with
the “typical” initial laboratory findings illustrates the risk
of misinterpreting the infection at a first glance.
To our knowledge, no risk factors for PVL-positive infec-
tions have been defined so far. However, it is well known
that sharing of personal items, particularly in sports clubs
and poor hygiene practices, including insufficient disin-
fection and protection of skin lesions, increase the rate
of PVL-related infections [17]. Among other factors that
increase the suspicion are non-white ethnicity, preceding
injury, contact sport, recent travel and influenza or other
respiratory infection [9, 11]. Our results correspond with
these, apart from influenza status, which was not tested in
our patients given the lack of relevant symptoms of pneu-
monia. The risk factors listed here overlap with the risk
factors for transmission of MSSA and MRSA. Therefore,
no PVL-specific risk factors were identified. Controversy
persists as to whether nasal carriage of PVL is systemat-
ically linked to infection [17, 18]. Since nasopharyngeal
swabs was tested in only one of our patients, we cannot
comment on this potential coherence.
The rate of complications is recognised to be high with
PVL-producing S. aureus infections. In our series, we
recorded orthopaedic and psychological sequels. Two of
them merit particular attention: a pathological fracture,
which occurred in the context of an underlying oncological
disease following local PVL infection; and suicidality in
a patient with a particularly long evolution, requiring 8
weeks of hospitalisation followed by 30 weeks of peroral
antibiotic treatment. Interestingly, one of the antimicrobial
agents used in the latter case was levofloxacin, a substance
known to potentially favour psychological deterioration
(swissmedic database). Hence, these observations highlight
multiple facets of PVL-positive infections: a rapidly evolv-
ing disease with the need for urgent invasive treatment and
the potential for multiple long-term sequels. However, nei-
ther of our cases suffered from pulmonary involvement or
thrombosis [3].
Despite the low prevalence of PVL in our area, PVL repre-
sents an important component in the cascade of paediatric
musculoskeletal infections. The observed rapid deteriora-
tion, the high recurrence rate and the long list of com-
plications underline the need for early and targeted treat-
ment. Generally, a combination of an anti-staphylococcal
regimen (amoxicillin / clavulanic acid or flucloxacillin)
and an anti-toxic agent blocking bacterial protein-synthesis
of PVL (clindamycin, linezolid, or gentamicin) is recom-
mended [8, 14, 19]. Antibiotic therapy is essential, yet not
exclusive. Inhibition of PVL production requires an anti-
staphylococcal agent at a drug concentration that ranges
far above the minimal inhibitory concentration at the site
of infection [19]. Insufficient dosage of β-lactams and,
to a lesser extent, vancomycin have been shown to even
enhance PVL secretion, thus aggravating the symptoms
[19–21]. Antibiotic treatment is even more challenging in
the case of CA-MRSA, where the use of β-lactams is lim-
ited. Consequently, standard care limited to antibiotic ther-
apy (even in the case of approved regimens) results in
failure of treatment in 85% of cases [19], especially as an-
tibiotic distribution is reduced in necrotic tissue. Therefore,
surgery plays a major role in achieving a positive outcome.
Early and complete removal of PVL suppuration from the
body and debridement of necrotic tissues with surgery is
a mandatory goal in treatment [19]. Surgical resection of
affected areas is mandatory to stop the circle of encapsu-
lation of bacteria and their toxin. According to the litera-
ture, 71% of patients with bone and joint infections require
more than one procedure, with a median of three interven-
tions per patient [19], which is consistent with our results.
In soft tissue infections, outcomes are particularly depen-
dent on surgical drainage and remain favourable, even in
the event of inappropriate antibiotic treatment [19].
Conclusion
Paediatric musculoskeletal infections by Panton-Valentine
leucocidin represent a rare, but highly dangerous entity.
They are characterised by rapid local extension and aggra-
vation despite antibiotic treatment. A discordance of low/
normal leucocyte count and high inflammatory parameters
(CRP) may be present at the time of diagnosis. Suspect-
ed cases require rapid identification of the toxin and ear-
ly, comprehensive imaging. Successful treatment relies on
surgical interventions with two-agent antimicrobial thera-
py, and a multidisciplinary approach by health profession-
als of paediatrics, paediatric surgery, radiology and infec-
tious diseases.
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